Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

K. Yamazaki, T. Yamanaka, M. Shiozawa, D. Manaka, M. Kotaka, M. Gamoh, A. Shiomi, A. Makiyama, Y. Munemoto, T. Rikiyama, M. Fukunaga, T. Ueki, K. Shitara, H. Shinkai, N. Tanida, E. Oki, E. Sunami, A. Ohtsu, Y. Maehara, T. Yoshino

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Fingerprint Dive into the research topics of 'Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences